UCB SA (0NZT)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 269.30 |
|---|---|
| 52-week range | 197.45 – 289.50 |
| Return, 1 month / 3 months | +27.5% / +11.4% |
| Return, 1 year / 3 years | +9.7% / +282.8% |
| Trend | Uptrend |
| RSI (14) | 81 |
| Volatility (1 year) | 38.5% |
| Worst drawdown (1 year) | -30.3% |
| Average daily value traded | 13.03M EUR |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UCB is a biopharmaceutical company based in Belgium that researches and develops medicines for people with serious diseases, particularly in neurology and immunology. Its products include treatments for epilepsy, Parkinson's disease and restless legs syndrome, as well as biologic therapies for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. The company serves patients and healthcare professionals through its own sales organisations in many countries and through partnerships with other pharmaceutical firms.
On this site UCB SA appears as a stock on the London Exchange (UK), code 0NZT, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UCB SA (0NZT) trades on the London Exchange in UK. It last closed at EUR 269.30 on 23 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,776 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 9.7% and over the last three months it rose 11.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 11.6% | ||
| From 52-week high | -5.6% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 11.4% | ||
| 6-month return | 9.5% | ||
| 12-month return, skipping the last month | -14.0% | ||
| Stability (higher is calmer) | 46 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.3% | ||
| Liquidity | 76 · Strong | Trades actively. | |
| Average daily value traded | 13.03M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +31.9% |
|---|---|
| 1 month | +27.5% |
| 3 months | +11.4% |
| 6 months | +9.5% |
| 1 year | +9.7% |
| 3 years | +282.8% |
| 5 years | +174.8% |
Signals
| 50-day / 200-day average | 212.78 / 241.39 |
|---|---|
| Golden / death cross (60 days) | Death, 51 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 8.43 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 May 2026 | EUR 1.0150 |
| 25 Apr 2025 | EUR 0.9730 |
| 26 Apr 2024 | EUR 0.9520 |
| 28 Apr 2023 | EUR 0.9310 |
| 29 Apr 2022 | EUR 0.9100 |
| 30 Apr 2021 | EUR 0.8890 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.